Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Somatic p.T771R KDR (VEGFR2) Mutation Arising in a Sporadic Angioma During Ramucirumab Therapy.

JAMA dermatology - 1 Nov 2015

Lim Young H, Odell Ian D, Ko Christine J, Choate Keith A

Abstract excerpt

IMPORTANCE: Inhibition of angiogenesis is an effective anticancer strategy because neoplasms require a rich blood supply. Ramucirumab, approved by the US Food and Drug Administration in 2014 to treat gastric adenocarcinomas and non-small cell lung carcinomas, targets vascular endothelial growth factor 2 (VEGFR2). We identified a patient prescribed a regimen of irinotecan hydrochloride, cetuximab, and ramucirumab...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Camptothecin

Share to Cetuximab

Share to Hemangioma

Share to Irinotecan

Share to Rectal Neoplasms

Share to Vascular Endothelial Growth Factor Receptor-2

Source

Identifiers

PMID: 26422291
DOI: 10.1001/jamadermatol.2015.1925

Genes

KDR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Somatic p.T771R KDR (VEGFR2) Mutation Arising in a Sporadic Angioma During Ramucirumab Therapy.PMID 26422291Read ↗

Case report: whole exome sequencing of primary cardiac angiosarcoma highlights potential for targeted therapies.Semantic proximity Read ↗

Comparative Genomics Reveals Shared Mutational Landscape in Canine Hemangiosarcoma and Human AngiosarcomaSemantic proximity Read ↗

Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathwaySemantic proximity Read ↗

Use of Targeted Next-Generation Sequencing to Identify Activating Hot Spot Mutations in Cherry AngiomasSemantic proximity Read ↗

Genomic analysis reveals shared genes and pathways in human and canine angiosarcomaSemantic proximity Read ↗

Mutational landscape of primary breast angiosarcoma with repeated resection and recurrence over a 15-year period: A case report.Semantic proximity Read ↗

Identification of genomic alterations with clinical impact in canine splenic hemangiosarcomaSemantic proximity Read ↗

Real-world evidence couples genomic biomarkers with therapeutic outcomes for canine hemangiosarcomaSemantic proximity Read ↗

Recurrent PTPRB and PLCG1 mutations in angiosarcoma.Semantic proximity Read ↗

Subclonal IDH1/2 Mutations as a Targetable Vulnerability in Vascular TumorsSemantic proximity Read ↗

Phospholipase C gamma 1 (PLCG1) R707Q mutation is counterselected under targeted therapy in a patient with hepatic angiosarcoma.Semantic proximity Read ↗

Primary Uterine Angiosarcoma Presenting With Omental Metastasis, Lymph Node Involvement, and Demonstrating a Null p53 Mutational Staining Pattern.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.